Takeda said to consider $3 billion product sale in emerging markets

Japanese drugmaker Takeda (TYO: 4502) is said to be considering a sale of certain therapies in emerging markets, with the aim of reducing its debt burden in the wake of its $62 billion purchase of rare disease specialist Shire.

According to press reports, Takeda is considering offloading assets that it picked up after buying Swiss company Nycomed.

Sources inside the company told Bloomberg that Takeda is mulling a sale of both over-the-counter and prescription medications, and that the total value of assets under consideration could be up to $3 billion.